Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rinaldi, M.
Right arrow Articles by Vigano, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rinaldi, M.
Right arrow Articles by Vigano, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Left ventricular assistance from bridge to transplantation to destination therapy. The Pavia experience

Mauro Rinaldi*, Francesco Pagani, Fabrizio Gazzoli, Alessia Alloni, Davide Ricci and Mario Vigano

Department of Cardiac Surgery, University of Pavia, Pavia, Italy

* Correspondence: Mauro Rinaldi, MD, Department of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy. Tel.: +39382503520; fax: +39382503059 (E-mail: m.rinaldi{at}smatteo.pv.it).

Abstract

OBJECTIVE: The increasing number of patients awaiting heart transplant and the shortage of donors led to the development of a variety of left ventricular assist devices (LVAD). We analyse our experience in order to evaluate the efficacy of LVAD as bridge to transplant and the feasibility of permanent implantation.

PATIENTS: The data are drawn from our experience on 50 patients, implanted with the Novacor LVAD and from a limited series of 4 patients implanted with a Lion Heart totally implantable permanent LVAD.

RESULTS: Seventeen patients died on the device, 32 underwent heart transplant (9 died after transplant) and one is still on device. The causes of death were mostly related to cerebrovascular events or multi-organ failure. Cardiac output, wedge pressure, pulmonary vascular resistance and mean pulmonary pressure improved significantly. Cerebrovascular complications occurred mostly during the first 3 months of assistance, whereas the incidence of infections remained constant during the follow-up period. With a mean time of assistance of 211 days, we had only two cases of device malfunction. The four Lion-Heart patients experienced a clear improvement in hemodynamics but at a price of a significant complication rate. Three of them died after 418, 105 and 380 days of assistance. Device malfunction was observed in two cases.

CONCLUSIONS: LVAD Novacor has shown good hemodynamic improvement and reliable mechanical performance and long-term bridging can be considered fairly safe since most complications seem to occur within the first 90 days. Destination therapy with totally implantable devices seems to need further engineering and technical development.

Keywords Heart failure; Ventricular assist device; Mechanical support; Heart transplant; Destination therapy; Bridge to transplant


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.